Join with us to hear about how QUT is working with TRI-based A/Prof Sally-Anne Stephenson to commercialise her research, including the creation of the start-up company, Kimaritec.

Speakers

A/Prof Sally-Anne Stephenson
Group Leader, Protein Ablation Cancer Therapeutics, QUT
A/Prof Sally Stephenson is a teaching and research academic at the Queensland University of Technology.  She leads the Protein Ablation Cancer Therapeutics (PACT) group which is currently part of the QUT contingent Level 3 TRI.  The PACT team design, develop and test small molecules targeting post-translational modifications important to the function of cancer relevant proteins. 

Dr Andrew Leech
Director Industry Engagement-Health, QUT
Since completing a postdoctoral research fellowship in the USA and earning his qualifications as a patent and trademark attorney, Andrew has spent his career helping university academics to establish industry partnerships and commercialise their research. Having worked at institutions all up and down the east coast of Australia, he has a broad range of experience in different technical areas, but as the Director Industry Engagement – Health at QUT Andrew focuses on development and commercialisation of therapeutic and medical devices through licensing and spinout companies.